Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy, 2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (20 November 2024) | Viewed by 5559
Special Issue Editor
Interests: hepatocellular carcinoma; immunotherapy; gastric cancer; HCC; renal cell carcinoma; urothelial carcinoma; biliary tract cancer; cholangiocarcinoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Emerging immune checkpoint inhibitors (ICIs) have also made progress in HCC, with two PD-1 inhibitors—nivolumab and pembrolizumab—both being approved by the United States Food and Drug Administration (FDA). ICIs alone as a first-line treatment have not achieved the desired effect; however, clinical trials evaluating combinatorial strategies involving ICIs and other anticancer agents, especially antiangiogenic agents, have produced more compelling results, marking a new era in HCC management. The Practice-Changing Phase III IMbrave150 Trial compared the use of a combination of the PD-L1 inhibitor atezolizumab and bevacizumab versus sorafenib monotherapy in treatment-naïve patients with advanced HCC and showed that combination therapy resulted in higher median overall survival (OS), median progression-free survival (PFS) benefit, and overall response rate (ORR). Atezolizumab–bevacizumab is also currently recognized as the new standard of care in front-line HCC and has been approved for use in several countries worldwide. Similarly, other combinations have been tested and are currently being evaluated.
From this point of view, this Special Issue welcomes basic research, reviews, case reports, etc., on the current state of the art in the immunotherapy of HCC.
Potential topics include, but are not limited to:
- Translational research;
- Molecular experiments on novel immune-based combinations;
- Real-world experience with immune checkpoint inhibitors;
- Fighting resistance to immune checkpoint inhibitors;
- Biomarker-driven studies.
Dr. Angela Dalia Ricci
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liver cancer
- hepatocellular carcinoma
- immunotherapy
- immune checkpoint inhibitors
- atezolizumab
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
